Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (NYSE MKT: IMUC) concerning possible violations of federal securities laws between May 1, 2012 and December 11, 2013 inclusive (the "Class Period"). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm in advance of the June 30, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here.

You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at

No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the Complaint, throughout the Class Period, ImmunoCellular issued materially false and/or misleading statements and/or failed to disclose: that ImmunoCellular retained Lidingo Holdings, LLC to publish promotional articles designed to unlawfully promote the Company; and that as a result of this scheme, the market was led to believe that the Company's clinical studies for its product candidate ICT-107 was going well and the share price was artificially inflated. When this information was released, the Company's stock price dropped materially, which harmed investors according to the Complaint. On April 10, 2017, the Securities and Exchange Commission announced enforcement actions against numerous individuals and entities, including ImmunoCellular, which engaged in stock promotion schemes.

Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders' rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on

Copyright Business Wire 2010